Trump may be mystery patient in case of 79yo getting experimental obesity drug
4 hours ago
- #compassionate use
- #obesity drug
- #retatrutide
- A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide via the FDA's compassionate use program.
- Retatrutide targets GIP, glucagon, and GLP-1 hormones and has shown significant weight loss results in trials.
- Only one person has been granted this early access, sparking speculation about the patient being former President Donald Trump.
- The patient has refractory obesity, obstructive sleep apnea, and pulmonary hypertension and had limited success with prior medication.